2015
Strategy for the Management of Macular Edema in Retinal Vein Occlusion: The European VitreoRetinal Society Macular Edema Study
Adelman RA, Parnes AJ, Bopp S, Othman I, Ducournau D. Strategy for the Management of Macular Edema in Retinal Vein Occlusion: The European VitreoRetinal Society Macular Edema Study. BioMed Research International 2015, 2015: 870987. PMID: 25705695, PMCID: PMC4325227, DOI: 10.1155/2015/870987.Peer-Reviewed Original ResearchConceptsRetinal vein occlusionCentral retinal vein occlusionBranch retinal vein occlusionVein occlusionMacular edemaVisual acuityIntravitreal antivascular endothelial growth factor injectionsAntivascular endothelial growth factor injectionsCases of RVOEndothelial growth factor injectionsGrowth factor injectionsChoice of treatmentMulticenter collaborative studyEdema studyFactor injectionsNonsurgical treatmentNumber of treatmentsVEGF injectionPlana vitrectomyRVO casesILM peelingRetina specialistsVisual gainDiagnostic findingsVisual improvement
2014
Aflibercept in the Treatment of Neovascular Age-Related Macular Degeneration in Previously Treated Patients
Hall LB, Zebardast N, Huang JJ, Adelman RA. Aflibercept in the Treatment of Neovascular Age-Related Macular Degeneration in Previously Treated Patients. Journal Of Ocular Pharmacology And Therapeutics 2014, 30: 346-352. PMID: 24552305, DOI: 10.1089/jop.2013.0188.Peer-Reviewed Original ResearchMeSH KeywordsAged, 80 and overAntibodies, Monoclonal, HumanizedBevacizumabFemaleHumansIntravitreal InjectionsMacular DegenerationMaleRanibizumabReceptors, Vascular Endothelial Growth FactorRecombinant Fusion ProteinsRetinaRetrospective StudiesTomography, Optical CoherenceTreatment OutcomeVascular Endothelial Growth Factor AVisual AcuityConceptsAge-related macular degenerationCentral macular thicknessAflibercept injectionsInitial visitMacular degenerationAnti-vascular endothelial growth factor treatmentNeovascular age-related macular degenerationEndothelial growth factor treatmentCentral macular edemaIntraocular pressure increaseSubset of patientsMain outcome measuresOptical coherence tomographyGrowth factor treatmentMacular thicknessNeovascular AgeOcular hypertensionSubmacular fluidVisual outcomeMacular edemaRetrospective studyVisual acuityOutcome measuresStudy populationPatients
2013
Incidence and Management of Elevated Intraocular Pressure with Antivascular Endothelial Growth Factor Agents
Abedi G, Adelman RA, Salim S. Incidence and Management of Elevated Intraocular Pressure with Antivascular Endothelial Growth Factor Agents. Seminars In Ophthalmology 2013, 28: 126-130. PMID: 23631423, DOI: 10.3109/08820538.2013.771195.Peer-Reviewed Original ResearchMeSH KeywordsAngiogenesis InhibitorsAntibodies, Monoclonal, HumanizedBevacizumabHumansIncidenceIntraocular PressureIntravitreal InjectionsOcular HypertensionRanibizumabVascular Endothelial Growth Factor AConceptsPersistent ocular hypertensionIntraocular pressureOcular hypertensionIntravitreal antivascular endothelial growth factorAntivascular endothelial growth factor agentsChronic intraocular pressure elevationEndothelial growth factor agentsIntravitreal anti-VEGF injectionsAntivascular endothelial growth factorAnti-VEGF injectionsGrowth factor agentsIntraocular pressure elevationElevated intraocular pressureElectronic literature searchEndothelial growth factorKey search termsFactor agentsPrompt diagnosisVEGF injectionAcute elevationIntravitreal injectionIOP elevationPersistent elevationPressure elevationGlaucomatous eyes
2012
Intravitreal Ranibizumab for Treatment of Choroidal Neovascularization Secondary to Angioid Streaks in Pseudoxanthoma Elasticum: Five-year Follow-up
Zebardast N, Adelman RA. Intravitreal Ranibizumab for Treatment of Choroidal Neovascularization Secondary to Angioid Streaks in Pseudoxanthoma Elasticum: Five-year Follow-up. Seminars In Ophthalmology 2012, 27: 61-64. PMID: 22784267, DOI: 10.3109/08820538.2012.680644.Peer-Reviewed Original ResearchMeSH KeywordsAngiogenesis InhibitorsAngioid StreaksAntibodies, Monoclonal, HumanizedChoroidal NeovascularizationFollow-Up StudiesHumansIntravitreal InjectionsMaleMiddle AgedPseudoxanthoma ElasticumRanibizumabTreatment OutcomeConceptsChoroidal neovascularizationOptical coherence tomographyPseudoxanthoma elasticumFluorescein angiographyNeovascular activityTreatment of CNVIntravitreal ranibizumab injectionsFive yearsMacular choroidal neovascularizationLong-term effectivenessOCT evidenceIntravitreal ranibizumabRanibizumab injectionsRanibizumab therapyAffected eyeIntraretinal fluidVisual acuityFluorescein leakageAngioid streaksScar formationInitial injectionCoherence tomographyRanibizumabInjectionNeovascularizationIs Intravitreal Bevacizumab an Effective Treatment Option for Nonarteritic Anterior Ischemic Optic Neuropathy?
Prescott CR, Sklar CA, Lesser RL, Adelman RA. Is Intravitreal Bevacizumab an Effective Treatment Option for Nonarteritic Anterior Ischemic Optic Neuropathy? Journal Of Neuro-Ophthalmology 2012, 32: 51-53. PMID: 22269947, DOI: 10.1097/wno.0b013e318240596e.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAngiogenesis InhibitorsAntibodies, Monoclonal, HumanizedBevacizumabFemaleHumansMaleMiddle AgedOptic Neuropathy, IschemicRetrospective StudiesVision, LowConceptsNonarteritic anterior ischemic optic neuropathyAnterior ischemic optic neuropathyIschemic optic neuropathyVisual acuityIntravitreal bevacizumabOptic neuropathyTreatment optionsIntravitreal bevacizumab injectionEffective treatment optionVisual field defectsBevacizumab injectionFellow eyesClinical outcomesRetrospective studyTreatment modalitiesNatural courseField defectsPatientsDecreased acuitySmall seriesAcuityBevacizumabProfound lossVisual fieldNeuropathy
2011
The Treatment of Recurrent Central Serous Chorioretinopathy with Intravitreal Bevacizumab
Lee ST, Adelman RA. The Treatment of Recurrent Central Serous Chorioretinopathy with Intravitreal Bevacizumab. Journal Of Ocular Pharmacology And Therapeutics 2011, 27: 611-614. PMID: 21810026, DOI: 10.1089/jop.2011.0045.Peer-Reviewed Original ResearchConceptsRecurrent central serous chorioretinopathyMean central macular thicknessCentral macular thicknessCentral serous chorioretinopathyPreinjection visual acuityVisual acuityOptical coherence tomographyIntravitreal bevacizumabSerous chorioretinopathyTreatment optionsLow-risk treatment optionYale Eye CenterIntravitreal bevacizumab injectionRetrospective case seriesEffective treatment optionLong-term efficacySub-retinal fluidNumber of injectionsFluorescein angiography imagingBevacizumab injectionRecurrent diseaseMacular thicknessMonth 3Month 6Case series
2010
Persistent Ocular Hypertension Following Intravitreal Bevacizumab and Ranibizumab Injections
Adelman RA, Zheng Q, Mayer HR. Persistent Ocular Hypertension Following Intravitreal Bevacizumab and Ranibizumab Injections. Journal Of Ocular Pharmacology And Therapeutics 2010, 26: 105-110. PMID: 20187807, DOI: 10.1089/jop.2009.0076.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedBevacizumabDrug Administration ScheduleDrug Therapy, CombinationFemaleHumansInjections, IntraocularIntraocular PressureMacular DegenerationMaleOcular HypertensionRanibizumabRetrospective StudiesTime FactorsVascular Endothelial Growth Factor AVitreous BodyConceptsAge-related macular degenerationPersistent ocular hypertensionOcular hypertensionIntraocular pressureIntravitreal bevacizumabRanibizumab injectionsIntravitreal injectionPrevious diagnosisGlaucoma/ocular hypertensionIntravitreal anti-VEGF injectionsAnti-VEGF injectionsIntravitreal bevacizumab injectionPostinjection intraocular pressurePreinjection intraocular pressureMultiple intravitreal injectionsTertiary referral centerRetrospective case seriesElevated intraocular pressureBevacizumab injectionIntravitreal ranibizumabReferral centerCase seriesVEGF injectionIOP increaseYAG capsulotomy
2009
Minimal Effects of VEGF and Anti-VEGF Drugs on the Permeability or Selectivity of RPE Tight Junctions
Peng S, Adelman RA, Rizzolo LJ. Minimal Effects of VEGF and Anti-VEGF Drugs on the Permeability or Selectivity of RPE Tight Junctions. Investigative Ophthalmology & Visual Science 2009, 51: 3216-3225. PMID: 20042644, PMCID: PMC2891474, DOI: 10.1167/iovs.09-4162.Peer-Reviewed Original ResearchAngiogenesis InhibitorsAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedBevacizumabBlood-Retinal BarrierCapillary PermeabilityCells, CulturedClaudinsElectric ImpedanceEnzyme-Linked Immunosorbent AssayFluorescent Antibody Technique, IndirectGene ExpressionHumansImmunoblottingPolyethylene GlycolsPotassiumRanibizumabRetinal Pigment EpitheliumReverse Transcriptase Polymerase Chain ReactionRNA, MessengerSodiumTight JunctionsVascular Endothelial Growth Factor AASSESSMENT OF OPTIC NERVE CUP-TO-DISK RATIO CHANGES IN PATIENTS RECEIVING MULTIPLE INTRAVITREAL INJECTIONS OF ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR AGENTS
SETH RK, SALIM S, SHIELDS MB, ADELMAN RA. ASSESSMENT OF OPTIC NERVE CUP-TO-DISK RATIO CHANGES IN PATIENTS RECEIVING MULTIPLE INTRAVITREAL INJECTIONS OF ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR AGENTS. Retina 2009, 29: 956-959. PMID: 19584654, DOI: 10.1097/iae.0b013e3181a91dfd.Peer-Reviewed Original ResearchMeSH KeywordsAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAptamers, NucleotideDrug Therapy, CombinationEyeFollow-Up StudiesFundus OculiHumansInjectionsIntraocular PressureOptic DiskOptic NerveRanibizumabRegional Blood FlowRetrospective StudiesSingle-Blind MethodVascular Endothelial Growth Factor AVitreous BodyConceptsMultiple intravitreal injectionsAnti-VEGF agentsIntraocular pressure riseIntraocular pressure fluctuationIntravitreal injectionMean changeControl groupTransient intraocular pressure riseSignificant differencesDisc ratio changesOptic nerve cupHistory of glaucomaAdditional prospective studiesGrowth factor effectsFellow eyesGlaucoma specialistsOptic nerveProspective studyOptic disc imagesFundus photographsTriamcinolone acetonideInclusion criteriaDisc ratioVertical cupPatients
2008
Are intravitreal bevacizumab and ranibizumab effective in a rat model of choroidal neovascularization?
Lu F, Adelman RA. Are intravitreal bevacizumab and ranibizumab effective in a rat model of choroidal neovascularization? Graefe's Archive For Clinical And Experimental Ophthalmology 2008, 247: 171. PMID: 18781316, DOI: 10.1007/s00417-008-0936-y.Peer-Reviewed Original ResearchMeSH KeywordsAngiogenesis InhibitorsAnimalsAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAptamers, NucleotideBevacizumabChoroidal NeovascularizationDisease Models, AnimalDose-Response Relationship, DrugFluorescein AngiographyInjectionsLight CoagulationMacular DegenerationRanibizumabRatsRats, Inbred BNVascular Endothelial Growth Factor AVitreous BodyConceptsLeakage of CNVTreatment of CNVPegaptanib sodiumChoroidal neovascularizationIntravitreal injectionRat modelBackgroundVascular endothelial growth factorAnti-VEGF agentsEffect of bevacizumabAnti-VEGF medicationsBrown Norway ratsEndothelial growth factorNon-human primatesAngiography 1Histopathologic toxicityIntravitreal bevacizumabCNV leakageFluorescein angiographyLaser photocoagulationBevacizumabTherapeutic effectCNV lesionsRanibizumabDay 1Important stimulator
2007
Choroidal Neovascularization Associated with West Nile Virus Chorioretinitis
Seth RK, Stoessel KM, Adelman RA. Choroidal Neovascularization Associated with West Nile Virus Chorioretinitis. Seminars In Ophthalmology 2007, 22: 81-84. PMID: 17564926, DOI: 10.1080/08820530701418375.Peer-Reviewed Original ResearchConceptsWest Nile virus chorioretinitisChoroidal neovascularizationChoroidal Neovascularization AssociatedLate-onset complicationsBest therapeutic optionGood anatomical responseNeovascularization AssociatedDiabetes mellitusLeft eyeIntravitreal injectionTherapeutic optionsChorioretinitisNeovascularizationBevacizumabPatientsInjectionMellitusComplicationsBaseline